Comparing Pulse Biosciences (PLSE) and Apyx Medical (APYX)

Pulse Biosciences (NASDAQ:PLSE) and Apyx Medical (NASDAQ:APYX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, valuation and institutional ownership.

Risk & Volatility

Pulse Biosciences has a beta of 1.7, meaning that its share price is 70% more volatile than the S&P 500. Comparatively, Apyx Medical has a beta of 0.38, meaning that its share price is 62% less volatile than the S&P 500.

Profitability

This table compares Pulse Biosciences and Apyx Medical’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Pulse Biosciences N/A -88.07% -80.02%
Apyx Medical 206.55% -8.95% -7.38%

Valuation and Earnings

This table compares Pulse Biosciences and Apyx Medical’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Pulse Biosciences N/A N/A -$37.54 million N/A N/A
Apyx Medical $16.69 million 15.95 $64.01 million ($0.29) -26.97

Apyx Medical has higher revenue and earnings than Pulse Biosciences.

Analyst Recommendations

This is a summary of recent ratings for Pulse Biosciences and Apyx Medical, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pulse Biosciences 0 0 1 0 3.00
Apyx Medical 0 0 1 0 3.00

Pulse Biosciences currently has a consensus target price of $27.00, suggesting a potential upside of 42.93%. Apyx Medical has a consensus target price of $10.00, suggesting a potential upside of 27.88%. Given Pulse Biosciences’ higher probable upside, analysts plainly believe Pulse Biosciences is more favorable than Apyx Medical.

Insider & Institutional Ownership

8.5% of Pulse Biosciences shares are held by institutional investors. Comparatively, 40.8% of Apyx Medical shares are held by institutional investors. 39.3% of Pulse Biosciences shares are held by company insiders. Comparatively, 5.7% of Apyx Medical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Apyx Medical beats Pulse Biosciences on 6 of the 9 factors compared between the two stocks.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc., a clinical-stage medical technology company, develops therapeutic tissue treatment platform based on its proprietary nano-pulse stimulation (NPS) technology. Its NPS is a non-thermal, precise, and focal drug-free tissue treatment technology that initiates cell death within treated tissue used in oncology, dermatology/aesthetics, minimally invasive, and veterinary applications. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was founded in 2014 and is headquartered in Hayward, California.

Apyx Medical Company Profile

Apyx Medical Corporation provides products in the cosmetic and surgical markets worldwide. The company markets Helium Plasma Technology under the Renuvion brand name in the cosmetic surgery market and under the J-Plasma brand name in the hospital surgical market. Its Renuvion cosmetic technology enables plastic surgeons, fascial plastic surgeons, and cosmetic physicians to provide controlled heat to the tissue to achieve their desired results; and the J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminating unintended tissue trauma. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.

Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.